Belangrijke publicaties uit de Hematologie
1. Den Heijer M, Gerrits WBJ, Haak HL, Wijermans PW,
Bos GMJ, Blom HJ, Rosendaal FR, Is
hyperhomocysteinaemia a risk factor for recurrent
venous thrombosis?, The Lancet. 1995;345:882-885.
2. Socié G, Stone JV, Wingard JR, Weisdorf D, HensleeDowney PJ, Bredeson C, Cahn JY, Passweg JR,
Rowlings PA, Schouten HC, Kolb HJ, Klein JP.
Long-term survival and late deaths after allogeneic
bone marrow transplantation Late Effects Working
Committee of the International Bone Marrow
Transplant Registry. N Engl J Med. 1999:14-21.
3. Schouten HC, Qian W, Kvaloy S, Porcellini A,
Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR,
Kvalheim G. High-dose therapy improves
progression-free survival and survival in relapsed
follicular non-Hodgkin’s lymphoma: results from
the randomized European CUP trial. J Clin Oncol.
2003:3918-27.
4. Löwenberg B, Pabst T, Vellenga E, van Putten W,
Schouten HC, Graux C, Ferrant A, Sonneveld P,
Biemond BJ, Gratwohl A, de Greef GE, Verdonck
LF, Schaafsma MR, Gregor M, Theobald M, Schanz
U, Maertens J, Ossenkoppele GJ, Dutch-Belgian
Cooperative Trial Group for Hemato-Oncology
(HOVON) and Swiss Group for Clinical Cancer
Research (SAKK) Collaborative Group. Cytarabine
dose for acute myeloid leukemia. N Engl J Med.
2011;364:1027-36.
5. Van Elssen CH, Vanderlocht J, Oth T, SendenGijsbers BL, Germeraad WT, Bos GM. Blood.
Inflammation-restraining effects of prostaglandin E2
on natural killer-dendritic cell (NK-DC) interaction
are imprinted during DC maturation. Blood.
2011;118:2473-82.
137
| Jan Scholte | Brian Scholtes | Mark Schonck | Erik Schoon | Thea Schoonbrood | Ellen Schoorel | Desirée van Schoubroeck | Harry Schouten | Gerben Schouten |